Gene expression profile in obesity and type 2 diabetes mellitus

Undurti N Das*1 and Allam A Rao2

Address: 1UND Life Sciences, 13800 Fairhill Road, #321, Shaker Heights, OH 44120, USA and 2Department of Computer Science and Systems Engineering, Andhra University, Visakhapatnam-530003, India

Email: Undurti N Das* - undurti@hotmail.com; Allam A Rao - apparaoallam@gmail.com

* Corresponding author

Abstract

Obesity is an important component of metabolic syndrome X and predisposes to the development of type 2 diabetes mellitus. The incidence of obesity, type 2 diabetes mellitus and metabolic syndrome X is increasing, and the cause(s) for this increasing incidence is not clear. Although genetics could play an important role in the higher prevalence of these diseases, it is not clear how genetic factors interact with environmental and dietary factors to increase their incidence. We performed gene expression profile in subjects with obesity and type 2 diabetes mellitus with and without family history of these diseases. It was noted that genes involved in carbohydrate, lipid and amino acid metabolism pathways, glycan of biosynthesis, metabolism of cofactors and vitamin pathways, ubiquitin mediated proteolysis, signal transduction pathways, neuroactive ligand-receptor interaction, nervous system pathways, neurodegenerative disorders pathways are upregulated in obesity compared to healthy subjects. In contrast genes involved in cell adhesion molecules, cytokine-cytokine receptor interaction, insulin signaling and immune system pathways are downregulated in obese. Genes involved in signal transduction, regulation of actin cytoskeleton, antigen processing and presentation, complement and coagulation cascades, axon guidance and neurodegenerative disorders pathways are upregulated in subjects with type 2 diabetes with family history of diabetes compared to those who are diabetic but with no family history. Genes involved in oxidative phosphorylation, immune, nervous system, and metabolic disorders pathways are upregulated in those with diabetes with family history of diabetes compared to those with diabetes but with no family history. In contrast, genes involved in lipid and amino acid pathways, ubiquitin mediated proteolysis, signal transduction, insulin signaling and PPAR signaling pathways are downregulated in subjects with diabetes with family history of diabetes. It was noted that genes involved in inflammatory pathway are differentially expressed both in obesity and type 2 diabetes. These results suggest that genes concerned with carbohydrate, lipid and amino acid metabolic pathways, neuronal function and inflammation play a significant role in the pathobiology of obesity and type 2 diabetes.

Introduction

Metabolic syndrome X is characterized by (a) abdominal obesity, (b) atherogenic dyslipidemia, (c) raised blood pressure, (d) insulin resistance with or without glucose intolerance, (e) pro-inflammatory state, and (f) pro-thrombin state. Thus, subjects who have abdominal obesity, atherosclerosis, insulin resistance and hyperinsulinemia, hyperlipidemias, endothelial dysfunc-
Obesity is a low-grade systemic inflammatory condition [1,2]. Plasma levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), markers of inflammation are elevated in subjects with obesity, insulin resistance, essential hypertension, type 2 diabetes, and CHD both before and after the onset of these diseases [3-9]. Overweight children and adults showed an increase in CRP concentration compared with normal weight children [3]. In these subjects, a direct correlation between the degree of adiposity and plasma CRP levels was noted. Elevated CRP concentrations has been shown to be associated with increased risk for CHD, ischemic stroke, peripheral arterial disease, and ischemic heart disease mortality in healthy men and women. A strong relation between elevated CRP levels and cardiovascular risk factors: fibrinogen, and HDL cholesterol was also reported. Furthermore, weight reduction and/or exercise decrease serum concentrations of TNF-α and simultaneously a reduction in the risk of CHD is also noted. This is supported by the observation that a negative correlation exists between plasma TNF-α and HDL cholesterol, glycosylated hemoglobin, and serum insulin concentrations that could explain as to why CHD is more frequent in obese compared to healthy or lean subjects [3,9]. Despite these evidences showing the relationship between inflammatory markers and obesity, type 2 diabetes mellitus, and CHD, the exact genetic relationship between these diseases is not clear. Hence in the present study, we performed gene expression profile in subjects with obesity and type 2 diabetes mellitus with and without family history to know the role of genetics in the pathobiology of these two diseases.

Materials and methods

Blood samples were obtained from 6 subjects. Of which: one was a healthy normal (H), one was healthy but was overweight (HO), one was obese (O), two were having type diabetes with no family history of diabetes (DNPH: DNPH1 and DNPH2), and one had type 2 diabetes whose parents were also diabetic (DPH). All these subjects were matched for age, gender, and body mass index. RNA was extracted from the peripheral blood leukocytes from these subjects, hybridized on Human 40K OciChip array (Ocimum Biosolutions, Hyderabad, India). Gene expression values were obtained after quantification of TIFF images. Data has 40,320 × 6 data points. Empty spots and control probes were removed before proceeding with data analysis. This study was approved by the Ethics Committee of Andhra University, Visakhapatnam, India., and the consent of all the participants was obtained.

Analysis performed

The data obtained was analyzed by two methods: (a) Differential expression analysis, and (b) Functional classification of differentially expressed genes.

Differential expression analysis

The primary objective of the study of gene expression profiles using microarray is to assess the mRNA transcript levels of samples under different experimental conditions and detect significant difference in expression levels of various genes across samples. When the number of replicates for each condition is adequate, the identification of differentially expressed genes is meaningful. However, in majority of instances, there are no or limited replicates due to practical constraints of cost and feasibility. In such an instance, appropriate statistical techniques are performed to arrive at information on differentially expressed genes.

For experiments with single sample in different conditions, it is assumed that the log intensity values of gene expression for the two samples are linearly related, following bivariate normal distribution, contaminated with outliers. In a contaminated bivariate distribution, the main body of the data is characterized by bivariate normal distribution and constitutes regular observations. The non-regular observations, described as outliers, represent systematic deviations. These outliers are often suspected as possible candidates for differential expression genes [10,11]. We have used this approach consisting of two-stages to detect outliers from bivariate population and determining differentially expressed candidate genes from these outliers. This approach provides the fold-change value considering the scatter of observations and thereby provides up and down regulated genes across the samples.

Methodology of analysis of data

Multivariate outlier detection

Outlier detection is one of the important tasks in any data analysis, which describes abnormalities in the data. Many methods have been proposed in the literature for detecting univariate outliers based on robust estimation of location and scale parameters [12-14]. The standard method
for multivariate outlier detection involves robust estimation of parameters in the Mahalanobis distance (MD) measure and then comparing MD with the critical value of $X^2$ distribution. The values larger than the critical value are treated as outliers of the distribution.

**Mahalanobis distance**

The shape and the size of multivariate data are quantified by the covariance matrix, which is taken into account in the Mahalanobis distance. Thus, for a multivariate sample $X_{ij}$, where $i = 1, 2, 3..., n$ (number of genes) and $j = 1, 2, 3... p$ (number of samples), the Mahalanobis distance is defined as,

$$MD_1 = ((x_{ij}-m)^TC^{-1}(x_{ij}-m))^{0.5}$$  \hspace{1cm} (1)

where $m$ is the estimated multivariate location parameter and $C$ is the estimated covariance matrix. For multivariate normal data, the squared MD values are approximately chi-square distributed with $p$ degrees of freedom. Multivariate outliers can now be defined as the observations having large (squared) MD values. A quantile for a chi-square distribution can be fixed (say 95%) and the observations with MD values greater than the chi-square cut-off at 95% are considered as outliers. The location and the covariance parameters are estimated using robust estimation methods. One of the well-known methods of estimation viz. Minimum Covariance Determinant (MCD) has been used in the study.

**Minimum covariance determinant (MCD)**

The MCD estimator is determined by that subset of observations of size $h$, which minimizes the determinant of the covariance matrix computed only from the $h$ observations. The location estimator is the average of these $h$ observations, whereas the scatter estimate is proportional to the variance covariance matrix. As a compromise between robustness and efficiency, usually $h = 0.75n$ ($n$ is the sample size) is used in the analysis. The distances obtained after using robust estimators are referred as robust distances (RD). Rousseeuw and Van Zomeren [15] have used these RDs for multivariate outlier detection, such that if the squared RD for an observation is larger than the chi-square cut-off at 95% are considered as outliers. The location and the covariance parameters are estimated using robust estimation methods. One of the well-known methods of estimation viz. Minimum Covariance Determinant (MCD) has been used in the study.

The tails will be defined by small $\delta = \chi^2_{p, 1-\alpha}$ for a certain small $\alpha$ (say 0.05). The vertical line in the figure indicates the cut-off value of chi-square for two degrees of freedom for 95% quantile. The observations with RD values greater than the cut-off are declared as outliers. Upon identifying the bivariate outliers, the next task is to identify those outlier genes that are differentially expressed across the two samples. The stage II level analysis deals with identifying a set of outlying genes that are differentially expressed.

**Stage II: Univariate outliers detection**

The univariate outliers detection analysis is performed as follows:

Let $S$ denote the original set of observations. Let $S_{out}$ and $S_{in}$ be the subsets of $S$ containing outlier and inlier observations respectively. Thus,

$$S_{out} \cup S_{in} = S \text{ and } S_{out} \cap S_{in} = \{\emptyset\}, \text{ i.e. the two subsets are mutually exclusive.}$$

We denote:

$$S_{out} = \{(\log_2(X_{i1}), \log_2(X_{i2}))/MD_i > c \text{ for } i = 1, 2, 3..... n\}$$

and

$$S_{in} = \{(\log_2(X_{i1}), \log_2(X_{i2}))/MD_i \leq c \text{ for } i = 1, 2, 3..... n\}$$

where ‘$c$’ is the cut-off for a given quantile and $n$ is the total number of genes.

We define a statistic,

$$Z = \log_2 \left( \frac{X_{2i}}{X_{1i}} \right) = \log_2(X_2) - \log_2(X_1)$$

which is the log of the ratio of intensity values for different genes for the two samples. Here $X_1$ is treated as reference, while $X_2$ is treated as test sample. The statistic provides a measure of differential expression (DE) of genes across the samples. The genes showing at least $k$-fold change (usually $k = 2$, i.e. $Z = 1$) across the samples are considered to be DE genes. The appropriate choice of $k$ is important since it influences the number of DE genes. Here we propose a rationale for selecting $k$ for a given percentage of bivariate outliers.

We generate values for the statistic for the entire set as,

$$Z = \{z_i; i = 1, 2, 3, ......n\}$$

$$= \{\log_2(X_{12}/X_{11}); i = 1, 2, 3, .......n\}$$
For a perfect linear relationship between the two samples, the Z statistic becomes residual following normal distribution with mean $m$ and variance $S_e^2$.

The statistic is used to obtain Mahalanobis distance measure as,

$$MD_i^* = \left( \frac{Z_i - m}{S_e} \right)^2 \text{ for } i = 1, 2, 3, ..., n$$  \hspace{1cm} (2)

The transformed distance measure is supposed to follow chi-square distribution with one degree of freedom. The empirical distribution function of $MD^*$ could be obtained and compared with that of the cumulative distribution of chi-square with one degree of freedom. A cut-off could be selected for $MD^*$ such that the observations greater than the cut-off could be declared as outliers. We search for an optimal cut-off, so that the univariate subset of outliers does not include any of the bivariate inliers. In other words, if $R_{out}$ is a subset of univariate outliers and $S_{in}$ the subset of bivariate inliers of $S$, then the optimal cut-off could be obtained as,

$$C^*_{opt} = \inf\left\{ C_i / R_{out} \cap S_{in} \neq \emptyset \right\}$$

The optimal cut-off could be obtained programmatically thereby yielding a set of univariate outliers that overlap with a subset of multivariate outliers. Figure 1 shows the common outliers obtained by both the methods for an optimal cut-off value of 6.15.

The probability value for this cut-off could be obtained by referring to chi-square distribution with one degree of freedom, which is 0.0132. Thus, 1.3% of the genes are outliers and are differentially expressed across the two samples. The observations indicated by green spots is the subset of bivariate outliers, which could have been differentially expressed across the samples. The cut-off value could be used in equation (2) to obtain the $z$-value as,

$$Z = (S_e) \sqrt{C_{opt}} + m$$  \hspace{1cm} (3)

This $z$-value determines the log fold change resulting into bivariate outliers that could be the potential candidates for differential expression. In the above case, $z$ value is 1.31, suggests that the bivariate outliers with fold change of 2.5 ($21.31 = 2.48$) and above across the samples could be the DE candidates. Figure 2 shows thresholds for log 2.48-fold change and log 2-fold change. The log 2-fold change includes large number of bivariate inliers, which are eliminated by log 2.48-fold change. The observations above log 2.48-fold are declared as up regulated with reference to $X_1$, while those below log 0.4-fold are declared as down regulated.

Thus, the approach described above identifies DE candidates amongst those observations, which are non-regular for some predefined percentile value and thereby provides a rationale for selecting the k-fold change.

![Figure 1](image1)

**Figure 1**
Outliers obtained using bivariate and univariate approaches.

![Figure 2](image2)

**Figure 2**
The up and down regulated genes for 2.48- and 2-log fold change thresholds.
Applying these principles to the present study, in the present context, there are six individuals, one from each of the categories namely healthy (H), healthy with obesity (H&O), obesity only (O), diabetes with parental history (DPH) and two individuals having diabetes without parental history (DNPH1 and DNPH2). The expression levels of 39,400 genes for each individual were obtained and compared pair wise, resulting into fifteen combinations. The analysis was carried out for each of these combinations independently following the afore stated approach. Prior to analysis, the data for each combination was normalized using Loess normalization. Below we present the analysis for each combination along with the interpretations.

**Results**

1. Healthy (reference) vs Healthy with overweight (test sample) [H vs H&O]

In the first step, the log intensity values of the gene expression for the two samples were preprocessed using loess method, in order to remove any measurement bias in the experiment. Figure 3 shows the MA-plots for before and after Loess normalization. Upon normalizing the expression values for the two samples, the scatter plot of log intensity values was obtained as shown in Figure 4. The scatter plot gives the bivariate distribution along with contaminated observations (genes)/outliers. The Mahalanobis distance measure was used to identify outliers for \( p = 0.10 \). Thus out of 39,400 genes, 3,940 genes were identified as outliers as indicated by red spots in Figure 5.

The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value (\( c^* \)). Figure 6 shows the thresholds for 2.36-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 1,247 were detected as up regulated, while 331 were detected as down-regulated genes with respect to the healthy (H) individual. Thus, for healthy vs. healthy with obesity comparison, 1,578 genes were found to be differentially expressed out of 39,400, which amounts to 4% of the total genes under study. This is 2.7% less than the number of genes obtained for 2-fold change thresholds. We refer 2.36 as the modified fold change, which is obtained based on the scatter of the distribution. More the scatter, larger is the modified fold change, thereby reducing the number of DE genes. The up and down regulated genes for the two categories were further considered for Gene Ontology (GO) and pathway analysis. On similar lines, the analysis was carried out for the remaining fourteen comparisons and the corresponding figures for each comparison are given below.

2. Healthy (reference) vs Obesity (test sample) [H vs O]

The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off

Figure 3
MA-plots showing scatter of expression values before and after Loess normalization for healthy vs. healthy with obesity comparison.
respect to the healthy (H) individual. Thus, for healthy vs.
obesity comparison, 1,951 genes were found to be differ-
entially expressed out of 39,400, which amounts to 4.9%

Figure 4
Scatter plot of log intensities for healthy vs. healthy with
obesity comparison after Loess normalization.

Figure 5
Bivariate outliers based on Mahalanobis distance measure for
p = 0.10 for healthy vs. healthy with obesity comparison.

Figure 6
The thresholds for 2.36 and 2 fold change values. The green
spots are the differentially expressed outlier genes for
healthy vs. healthy with obesity comparison.

Figure 7
The thresholds for 2.94 and 2 fold change values. The green
spots are the differentially expressed outlier genes for
healthy vs. obesity comparison.

(c*). Figure 7 shows the thresholds for 2.94-fold change,
thereby providing the up and down regulated genes. Out
of 3,940 outlier genes, 962 were detected as up regulated,
while 989 were detected as down-regulated genes with

(c*). Figure 7 shows the thresholds for 2.94-fold change,
thereby providing the up and down regulated genes. Out
of 3,940 outlier genes, 962 were detected as up regulated,
while 989 were detected as down-regulated genes with
of the total genes under study. This is 6% less than the number of genes obtained for 2-fold change thresholds.

3. Healthy (reference) vs Diabetic with no parental history1 (test sample) [H vs DNPH1]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value (c*). Figure 8 shows the thresholds for 2.37-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 1,249 were detected as up regulated, while 477 were detected as down-regulated genes with respect the healthy (H) individual. Thus, for healthy vs. diabetic with no parental history (1) comparison, 1,726 genes were found to be differentially expressed out of 39,400, which amounts to 4.3% of the total genes under study. This is 3.3% less than the number of genes obtained for 2-fold change thresholds.

4. Healthy (reference) vs Diabetic with no parental history2 (test sample) [H vs DNPH2]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value (c*). Figure 9 shows the thresholds for 2.96-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 861 were detected as up regulated, while 356 were detected as down-regulated genes with respect to the healthy (H) individual. Thus, for healthy vs. diabetic with no parental history [2] comparison, 1,217 genes were found to be differentially expressed out of 39,400, which amounts to 3% of the total genes under study. This is 7% less than the number of genes obtained for 2-fold change thresholds. It can be seen from the results depicted in Figures 8 and 9 that even though both subjects [1 and 2] are having type 2 diabetes mellitus with no parental history of diabetes, the genes that were differentially expressed compared to healthy control were slightly different between the two [1 and 2]. But, on the whole the differentially expressed genes were similar (compare figure 8 and 9).

5. Healthy (reference) vs Diabetic with parental history (test sample) [H vs DPH]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value (c*). Figure 10 shows the thresholds for 2.36-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 1,211 were detected as up regulated, while 368 were detected as down-regulated genes with respect to the healthy (H) individual. Thus, for healthy vs. diabetic with parental history comparison, 1,579 genes were found to be differentially expressed out of 39,400, which amounts to 4% of the total genes under study. This is 2.73% less than the number of genes obtained for 2-fold change thresholds.

6. Healthy with overweight (reference) vs Obesity (test sample) [HO vs O]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off
value ($c^*$). Figure 11 shows the thresholds for 2.38-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 814 were detected as upregulated, while 1,469 were detected as down-regulated genes with respect to healthy individual with overweight (HO). Thus, for healthy with obesity vs. obesity comparison, 2,283 genes were found to be differentially expressed out of 39,400, which amounts to 5.8% of the total genes under study. This is 2.6% less than the number of genes obtained for 2-fold change thresholds.

7. Healthy with Overweight (reference) vs Diabetic with no parental history1 (test sample) [HO vs DNPH1]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value ($c^*$). Figure 12 shows the thresholds for 2.14-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 539 were detected as upregulated, while 1,058 were detected as down-regulated genes with respect to healthy individual with overweight (HO). Thus, for healthy with overweight vs. diabetic with no parental history [1] comparison, 1,597 genes were found to be differentially expressed out of 39,400, which amounts to 4% of the total genes under study. This is 1.2% less than the number of genes obtained for 2-fold change thresholds.

8. Healthy with Overweight (reference) vs Diabetic with no parental history2 (test sample) [HO vs DNPH2]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value ($c^*$). Figure 12 shows the thresholds for 2.14 and 2 fold change values. The green spots are the differentially expressed outlier genes for healthy with overweight vs. diabetic with no parental history comparison.
value (c*). Figure 13 shows the thresholds for 2.43-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 541 were detected as up regulated, while 672 were detected as down-regulated genes with respect to healthy individual with obesity (HO). Thus, for healthy with overweight vs. diabetic with no parental history [2] comparison, 1,213 genes were found to be differentially expressed out of 39,400, which amounts to 3% of the total genes under study. This is 2.75% less than the number of genes obtained for 2-fold change thresholds. When the results given in Figures 12 and 13 are compared they look very similar. This suggests that, in general, the differentially expressed genes between healthy with overweight vs. those with type 2 diabetes mellitus (even when compared with two distinctly different individuals) with no parental history are almost identical.

9. Healthy with Overweight (reference) vs Diabetic with parental history (test sample) [HO vs DPH]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value (c*). Figure 14 shows the thresholds for 2.07-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 502 were detected as up regulated, while 822 were detected as down-regulated genes with respect to healthy individual with overweight (HO). Thus, for healthy with overweight vs. diabetic with parental history comparison, 1,324 genes were found to be differentially expressed out of 39,400, which amounts to 3.3% of the total genes under study. This is 0.05% less than the number of genes obtained for 2-fold change thresholds.

10. Obesity (reference) vs Diabetic with no parental history1 (test sample) [O vs DNPH1]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off (c*). Figure 15 shows the thresholds for 2.07-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 1,479 were detected as up regulated, while 1,333 were detected as down-regulated genes with respect the individual with obesity (O). Thus, for obesity vs. diabetes with no parental history [1] comparison, 2,812 genes were found to be differentially expressed out of 39,400, which amounts to 7.1% of the total genes under study. This is 0.06% less than the number of genes obtained for 2-fold change thresholds.

11. Obesity (reference) vs Diabetic with no parental history2 (test sample) [O vs DNPH2]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value (c*). Figure 16 shows the thresholds for 2.39-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 1,534 were detected as
up regulated, while 813 were detected as down-regulated genes with respect the individual with obesity (O). Thus, for obesity vs. diabetic with no parental history comparison, 2,347 genes were found to be differentially expressed out of 39,400, which amounts to 5.95% of the total genes under study. This is 2.6% less than the number of genes obtained for 2-fold change thresholds.

12. Obesity (reference) vs Diabetic with parental history (test sample) [O vs DPH]

The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value (c*). Figure 17 shows the thresholds for 2.17-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 1,338 were detected as up regulated, while 1,002 were detected as down-regulated genes with respect the individual with obesity. Thus, for obesity vs. diabetic with parental history comparison, 2,340 genes were found to be differentially expressed out of 39,400, which amounts to 5.93% of the total genes under study. This is 1% less than the number of genes obtained for 2-fold change thresholds.

13. Diabetic with no parental history1 (reference) vs Diabetic with no parental history2 (test sample) [DNPH1 vs DNPH2]

Here we compared gene expression profile between two subjects with type 2 diabetes mellitus whose parents were also diabetic. The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value (c*). Figure 18 shows the thresholds for 2.18-fold change, thereby providing the up and down regulated genes.

The thresholds for 2.17 and 2.18 fold change values.
regulated genes. Out of 3,940 outlier genes, 948 were detected as up regulated, while 662 were detected as down-regulated genes with respect to the individual with diabetes and no parental history [1]. Thus, a comparison between two individuals who were both diabetic with no parental history [1 and 2], 1,610 genes were found to be differentially expressed out of 39,400, which amounts to 4% of the total genes under study. This is 1.5% less than the number of genes obtained for 2-fold change thresholds.

14. Diabetic with no parental history1 (reference) vs Diabetic with parental history (test sample) [DNPH1 vs DPH]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value ($c^*$). Figure 19 shows the thresholds for 2-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 686 were detected as up regulated, while 979 were detected as down-regulated genes with respect to the individual with diabetic and no parental history [2]. Thus, for diabetic with no parental history [2] vs. diabetic with parental history comparison, 1,655 were found to be differentially expressed out of 39,400, which amounts to 4.2% of the total genes under study. When figures 19 and 20 are compared, it is clear that the differentially expressed genes between diabetics with no parental history [subjects 1 and 2] vs diabetic with parental history are very similar. This suggests that even though subjects with diabetes with no parental history are different the expressions of genes are closely similar when compared with those seen in diabetics with parental history (see Figures 19 and 20).

15. Diabetic with no parental history2 (reference) vs Diabetic with parental history (test sample) [DNPH2 vs DPH]
The distribution of log fold change values was obtained and the outliers were detected for the optimum cut-off value ($c^*$). Figure 20 shows the thresholds for 2-fold change, thereby providing the up and down regulated genes. Out of 3,940 outlier genes, 676 were detected as up regulated, while 979 were detected as down-regulated genes with respect to the individual with diabetic and no parental history [2]. Thus, for diabetic with no parental history [2] vs. diabetic with parental history comparison, 1,655 were found to be differentially expressed out of 39,400, which amounts to 4.2% of the total genes under study. When figures 19 and 20 are compared, it is clear that the differentially expressed genes between diabetics with no parental history [subjects 1 and 2] vs diabetic with parental history are very similar. This suggests that even though subjects with diabetes with no parental history are different the expressions of genes are closely similar when compared with those seen in diabetics with parental history (see Figures 19 and 20).

Functional classification of differentially expressed genes
To determine biological significance of differentially expressed genes, functional classification was performed using Gene Ontology. Gene Ontology reports along with Z-scores give statistical significance, indicating relative representation up-regulated/down-regulated genes in
each function. To determine pathways associated with differentially expressed genes, pathway analysis was performed.

**Gene Ontology Analysis**

1. **Diabetes with parental history** vs **Normal** [DPH vs H]

   **Molecular Function**
   Genes involved in NADH dehydrogenase (ubiquinone) activity, glutamate dehydrogenase [NAD(P)+] activity, CDP-diacylglycerol-glycerol-3-phosphate-3-phosphatidyltransferase activity were upregulated in DPH with respect to H. Genes involved in protein kinase B binding, enzyme inhibitor activity, acyl-CoA oxidase activity, phosphati-
dylinositol transporter activity, acyltransferase activity were downregulated in DPH with respect to H.

   **Biological Process**
   Genes involved in synaptic vesicle membrane organization and biogenesis, polysaccharide metabolic process, regulation of growth rate, nucleosome assembly were upregulated in DPH with respect to H. Genes involved in immune response, regulation of glycolysis were downregulated in DPH with respect to H.

   **Cellular Component**
   Genes localized in cohesin core heterodimer, oligosacchar-
ryl transferase complex, nucleosome, respiratory chain complex II were upregulated in DPH with respect to H.

2. **Diabetes without parental history** I vs **Normal** [DNPH1 vs H]

   **Molecular Function**
   Genes involved in hydroxyacylglutathione hydrolase activity, NADH dehydrogenase (ubiquinone) activity, GABA-B receptor activity, glutamate dehydrogenase [NAD(P)+] activity, CDP-diacylglycerol-glycerol-3-phosphate-3-phosphatidyltransferase activity were upregulated in DNPH1 with respect to H. Genes involved in MHC class II receptor activity, structural constituent of ribosome, Hsp70 protein binding, L-tyrosine transporter activity, cyclin binding, arachidonate 5-lipoxygenase activity were downregulated in DNPH1 with respect to H.

   **Biological Process**
   Genes involved in synaptic vesicle membrane organization and biogenesis, plasma membrane organization and biogenesis, polysaccharide metabolic process, regulation of growth rate, regulation of pH were upregulated in DNPH1 with respect to H. Genes involved in establishment of cellular localization, cell activation, immune response were downregulated in DNPH1 with respect to H.

   **Cellular Component**
   Genes localized in vacuolar lumen, chromosome, nucleo-
some, proteasome activator complex were upregulated in DNPH1 with respect to H. Genes localized in ferritin complex, proton-transporting ATP synthase complex, coupling factor F(o), ribosome, eukaryotic translation elongation factor 1 complex, ubiquitin conjugating enzyme complex were downregulated in DNPH1 with respect to H.

3. **Type 2 diabetes mellitus without parental history** 2 vs **Normal** [DNPH2 vs H]

   **Molecular Function**
   Genes involved in asparaginase activity, creatine: sodium symporter activity, phosphomannomutase activity, glutamate dehydrogenase [NAD(P)+] activity, basic amino acid transporter activity, adenylsuccinate synthase activity were upregulated in D&NPH2 with respect to H. Genes involved in structural constituent of ribosome, MHC class II receptor activity, MHC class I receptor activity, L-tyro-
sine transporter activity, N-acylmannosamine kinase activity were downregulated in D&NPH2 with respect to H.

   **Biological Process**
   Genes involved in polysaccharide metabolic process, reg-
ulation of pH, aromatic compound biosynthetic process,
regulation of growth rate, lipid glycosylation were upregulated in D&NPH1 with respect to H. Genes involved in establishment of cellular localization, immune response, ribosome biogenesis and assembly were downregulated in D&NPH2 with respect to H.

**Cellular Component**
Genes localized in 4-aminobutyrate transaminase complex, oligosaccharyl transferase complex were upregulated in D&NPH1 with respect to H. Genes localized in ribosome, Arp2/3 protein complex, eukaryotic translation elongation factor 1 complex, small ribosomal subunit, ferritin complex, mitochondrial outer membrane translocase complex were downregulated in D&NPH2 with respect to H.

### 4. Obese vs Normal (O vs H)

**Molecular Function**
Genes involved in peptide deformylase activity, NADH dehydrogenase (ubiquinone) activity, glutamate dehydrogenase [NAD(P)+] activity, phosphomannomutase activity, transposase activity, carboxylic ester hydrolase activity, glutamate decarboxylase activity, mannosyltransferase activity, transforming growth factor beta binding were upregulated in O with respect to H. Genes involved in glycolipid transporter activity, glycolipid binding, 3-hydroxyisobutyrate dehydrogenase activity, 25-hydroxycholecalciferol-24-hydroxylase activity were downregulated in O with respect to H.

**Biological Process**
Genes involved in regulation of isoprenoid metabolic process, polysaccharide metabolic process, regulation of pH were upregulated in O with respect to H. Genes involved in synaptic vesicle membrane organization and biogenesis, cellular macromolecule catabolic process, locomotion during locomotor behavior were downregulated in O with respect to H.

**Cellular Component**
Genes localized in CAAX-protein geranylgeranyltransferase complex, intracellular organelle were upregulated in O with respect to H. Genes localized in vesicle, eukaryotic translation elongation factor 1 complex, perikaryon, Golgi transport complex are downregulated in O with respect to H.

### 5. Diabetes with parental history vs Obese [DPH vs O]

**Molecular Function**
Genes involved in glycolipid transporter activity, calmodulin inhibitor activity, glycolipid binding, interleukin-22 receptor activity, oxygen transporter activity, antigen binding, lactate dehydrogenase activity, glyoxylate reductase (NADP) activity, 25-hydroxycholecalciferol-24-hydroxylase activity, glycerate dehydrogenase activity, ubiquinol-cytochrome-c reductase activity were upregulated in DPH with respect to O. Genes involved in amylo-alpha-1, 6-glucosidase activity, 4-alpha-glucanotransferase activity, interleukin-8 receptor activity were downregulated in DPH with respect to O.

**Biological Process**
Genes involved in synaptic vesicle membrane organization and biogenesis, response to stimulus, cellular macromolecule catabolic process were upregulated in DPH with respect to O. Genes involved in regulation of isoprenoid metabolic process, blastocyst growth, regulation of glycolysis were downregulated in DPH with respect to O.

**Cellular Component**
Genes localized in vesicle hemoglobin complex, perikaryon, Golgi transport complex were upregulated in DPH with respect to O. Genes localized in isoamylase complex, CAAX-protein geranylgeranyltransferase complex, NADPH oxidase complex, protein kinase CK2 complex, MHC class I peptide loading complex, proteasome activator complex are downregulated in DPH with respect to O.

### 6. Genes that were similarly expressed both in diabetes and obesity [DPH and O]

**Molecular Function**
Genes involved in NADH dehydrogenase (ubiquinone) activity, glutamate dehydrogenase [NAD(P)+] activity, transposase activity, guanylate cyclase inhibitor activity were upregulated both in diabetes and obesity. Genes involved in hypoxanthine phosphoribosyltransferase activity, structural constituent of ribosome, NADP binding, histone deacetylase activity were downregulated in diabetes and obesity.

**Biological Process**
Genes involved in polysaccharide metabolic process, regulation of pH, tissue development, and diuresis were upregulated both in diabetes and obesity. Genes involved in regulation of hormone biosynthetic process, opsonization were downregulated in diabetes and obesity.

**Cellular Component**
Genes localized in oligosaccharyl transferase complex, cytoplasmic vesicle, ribosome are upregulated in diabetes and obesity. Genes localized in small ribosomal subunit, proton-transporting ATP synthase complex, coupling factor F(0) were downregulated in diabetes and obesity.

### 7. Obese vs overweight subjects with tendency towards Obesity (O vs HO)

**Molecular Function**
Genes involved in transforming growth factor beta binding, sodium: amino acid symporter activity, adenosylho-
mocysteinase activity, transferase activity, transferring acyl groups, caspase activator activity, NAD(P)H oxidase activity,

steroid 21-monooxygenase activity, malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) activity, glutamate decarboxylase activity were upregulated in O vs HO. Genes involved in creatine: sodium symporter activity, glycolipid transporter activity, glycolipid binding, 3-hydroxyisobutyrate dehydrogenase activity, leukemia inhibitory factor receptor activity, superoxide-generating NADPH oxidase activity, chemokine receptor activity, interleukin-22 receptor activity were downregulated in O vs HO.

**Biological Process**
Genes involved in establishment of cellular localization, cuticle biosynthetic process, hydrogen peroxide, biosynthetic process, vesicle docking were upregulated in O vs HO. Genes involved in synaptic vesicle membrane organization and biogenesis, response to stimulus, anatomical structure development were downregulated in O vs HO.

**Cellular Component**
Genes localized in CAAX-protein geranylgeranyltransferase complex were upregulated in O vs HO. Genes localized in Golgi transport complex, vesicle, oncostatin-M receptor complex, perikaryon were downregulated in O vs HO.

**8. Diabetes with parental history vs diabetes without parental history (DPH vs DNPH1)**

**Molecular Function**
Genes involved in MHC class II receptor activity, gamma-amino butyric acid: hydrogen symporter activity, chemokine receptor activity, interleukin-4 receptor activity, interleukin-7 receptor activity, arachidonate 5-lipoxygenase activity, complement receptor activity were upregulated in DPH vs DNPH1. Genes involved in ammonia ligase activity, transaldolase activity, 4-alpha-glucanotransferase activity, choline: sodium symporter activity, interleukin-8 receptor activity were downregulated in DPH vs DNPH1.

**Biological Process**
Genes involved in cell activation, macromolecule biosynthetic process, hydrogen peroxide biosynthetic process, immune response, regulation of glycolysis were upregulated in DPH Vs DNPH1. Genes involved in blastocyst growth, aromatic compound biosynthetic process, nitric oxide biosynthetic process, regulation of glycolysis were downregulated in DPH vs DNPH1.

**Cellular Component**
Genes localized in ribonucleosidediphosphate reductase complex, interleukin-18 receptor complex, interleukin-1 receptor complex, mitochondrion interleukin-5 receptor complex were upregulated in DPH vs DNPH1. Genes localized in proteasome activator complex, isoamylase complex, CAAX-protein geranylgeranyl-transferase complex, protein kinase CK2 complex, oxoglutarate dehydrogenase complex, MHC class I peptide loading complex were downregulated in DPH vs DNPH1.

**9. Diabetic with parental history of diabetes vs diabetic with no parental history of diabetes (DPH vs DNPH2)**

**Molecular Function**
Genes involved in structural constituent of ribosome, MHC class II receptor activity, ferroxidase activity, NAD(P)H oxidase activity were upregulated in DPH vs DNPH2. Genes involved in 4-alpha-glucanotransferase activity, phospho-mannomutase activity, receptor signaling protein tyrosine kinase activity were downregulated in DPH vs DNPH2.

**Biological Process**
Genes involved in intracellular sequestering of iron ion, ribosome biogenesis and assembly, hydrogen peroxide biosynthetic process were upregulated in DPH vs DNPH2. Genes involved in hemostasis, developmental growth, lipid glycosylation, regulation of glycolysis were downregulated in DPH vs DNPH2.

**Cellular Component**
Genes localized in ribosome, ferritin complex are upregulated in DPH vs DNPH2. Genes localized in CAAX-protein geranylgeranyltransferase complex, isoamylase complex, apolipoprotein B mRNA editing enzyme complex, lipopolysaccharide receptor complex, proteasome activator complex are downregulated in DPH vs DNPH2.

For easy understanding, a summary of the gene ontology analysis data is given in Table 1.

**Pathway Analysis**

1. **Diabetes with parental history vs Normal (DPH vs H)**
Genes involved in inositol phosphate metabolism, starch and sucrose metabolism, nitrogen metabolism, oxidative phosphorylation, androgen and estrogen metabolism, glycan biosynthesis and metabolism pathways, metabolism of cofactors and vitamins pathways, MAPK signaling pathway, ECM-receptor interaction, neuroactive ligand-receptor interaction, regulation of actin cytoskeleton, cell communication pathways, nervous system pathways, neurodegenerative disorders pathways were upregulated in DPH vs H. Genes involved in glycolysis/gluconeogenesis, propanoate metabolism, carbon fixation, biosynthesis of steroids, fatty acid metabolism, histidine metabolism, phenylalanine metabolism, tyrosine metabolism, urea cycle and metabolism of amino groups, cell cycle, insulin signaling pathway, PPAR signaling pathway, antigen...
processing and presentation were downregulated in DPH vs H.

**Molecular Function**

Genes involved in NADH dehydrogenase (ubiquinone) activity, glutamate dehydrogenase [NAD(P)+] activity, CDP-diacylglycerol-glycerol-3-phosphate-3-phosphatidyltransferase activity were upregulated in DPH with respect to H. Genes involved in protein kinase B binding, enzyme inhibitor activity, acyl-CoA oxidase activity, phosphatidylinositol transporter activity, acyltransferase activity were downregulated in DPH with respect to H.

| Comparison | Up regulated genes | Down regulated genes |
|------------|--------------------|----------------------|
| DPH vs H   | NADH dehydrogenase (ubiquinone) | Protein kinase B binding |
|           | Glutamate dehydrogenase [NAD(P)+] | Acyl-CoA oxidase |
|           | CDP-diacylglycerol-glycerol-3-phosphate-3-phosphatidyltransferase | Phosphatidylinositol transporter |
|           | Hydroxocysteine hydrolase | Acyltransferase |
|           | NADH dehydrogenase (ubiquinone) | MHC class II receptor |
|           | GABA-B receptor Glutamate dehydrogenase [NAD(P)+] CDP-diacylglycerol-glycerol-3-phosphate-3-phosphatidyltransferase | Structural constituent of ribosome |
|           | Protein kinase B binding | Hsp 70 protein binding |
|           | Acyl-CoA oxidase | L-tyrosine transporter |
|           | Phosphatidylinositol transporter | Cyclin binding Arachidonate 5-lipoxygenase |
|           | Acyltransferase | |
| DNPH1 vs H | Asparaginase activity | Structural constituent of ribosome |
|           | Creatine: sodium symporter | MHC class I receptor |
|           | Phosphomannomutase activity | L-tyrosine transporter |
|           | Glutamate dehydrogenase [NAD(P)+] basic amino acid transporter | N-acetylmannosamine kinase |
|           | Adenosylsucininate synthase | Glycolipid transporter activity |
|           | | Glycolipid binding |
|           | | 3-hydroxisobutyrate |
|           | | Dehydrogenase |
|           | | 23-hydroxycholecalciferol-24-hydroxylase |
| DNPH2 vs H | Deformylase | |
|           | | |
|           | | |
| O vs H    | Asparaginase activity | |
|           | Creatine: sodium symporter | |
|           | Phosphomannomutase activity | |
|           | Glutamate dehydrogenase [NAD(P)+] basic amino acid transporter | |
|           | Adenosylsucininate synthase | |
|           | | |
|           | | |
| DPH vs O  | Glycolipid transporter | |
|           | Calmodulin inhibitor | |
|           | Phosphomannomutase activity | |
|           | Glutamate dehydrogenase | |
|           | Interleukin-22 receptor | |
|           | Oxygen transporter | |
|           | Antigen binding | |
|           | Lactate dehydrogenase | |
|           | Glyoxylate reductase (NADP) activity | |
|           | 25-hydroxycholecalciferol-24-hydroxylase activity | |
|           | Glyceraldehyde dehydrogenase | |
|           | Ubiquinol-cytochrome c reductase | |
| DPH and O | NADH dehydrogenase (ubiquinone) Glutamate dehydrogenase [NAD(P)+] Transposase | Hypoxanthine phosphoribosyltransferase Structural constituent of Ribosome |
|           | Guanylate cyclase inhibitor | |
|           | | NADP binding, and histone deacetylase |
| O vs HO   | Transforming growth factor beta binding | |
|           | Sodium: amino acid symporter | |
|           | Adenosylhomocysteinecinease Transferase | |
|           | Transferring acyl groups | |
|           | Caspase activator | |
|           | NAD(P)+ oxidase | |
|           | Steroid 21-monoxygenase | |
|           | Malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) Glutamate decarboxylase | |
| DPH vs DNPH1 | MHC class II receptor | |
|           | Gamma-aminobutyric acid: hydrogen symporter | |
|           | chemokine receptor Interleukin-4 receptor Interleukin-7 receptor Arachidonate 5-lipoxygenase | |
|           | Complement receptor | |
| 8 DPH vs DNPH2 | Structural constituent of ribosome | |
|           | MHC class II receptor | |
|           | Ferrooxidase | |
|           | NAD(P)+ oxidase | |
| 9 DPH vs DNPH2 | Structural constituent of ribosome | |
|           | MHC class II receptor | |
|           | Ferrooxidase | |
|           | NAD(P)+ oxidase | |
2. Diabetes without parental history vs Normal [DNPH1 vs H]
Genes involved in carbohydrate metabolism pathways, metabolism of cofactors and vitamins pathways, ubiquitin mediated proteolysis, signal transduction pathways, ECM-receptor interaction, neuroactive ligand receptor interaction, regulation of actin cytoskeleton, cell cycle, endocrine system pathways, nervous system pathways, Huntington’s disease were upregulated in DNPH1 vs H. Genes involved in cell adhesion molecules (CAMs), antigen processing and presentation were downregulated in DNPH1 vs H.

3. Diabetes without parental history vs Normal [DNPH2 vs H]
Genes involved in carbohydrate metabolism pathways, lipid metabolism pathways, glycan biosynthesis and metabolism pathways, metabolism of cofactors and vitamins pathways, ubiquitin mediated proteolysis, signal transduction pathways, signaling molecules and interaction pathways, PPAR signaling pathway, GnRH signaling pathway, nervous system pathways, development pathways, neurodegenerative disorders pathways were upregulated in DNPH2 vs H. Genes involved in insulin signaling pathway, immune system pathways were downregulated in DNPH2 vs H.

4. Obese vs Normal [O vs H]
Genes involved in carbohydrate metabolism pathways, lipid metabolism pathways, amino acid metabolism pathways, glycan biosynthesis and metabolism pathways, metabolism of cofactors and vitamins pathways, ubiquitin mediated proteolysis, signal transduction pathways, neuroactive ligand-receptor interaction, nervous system pathways, neurodegenerative disorders pathways are upregulated in O vs H. Genes involved in cell adhesion molecules (CAMs), cytokine-cytokine receptor interaction, insulin signaling pathway, immune system pathways were downregulated in O vs H.

5. Diabetes with parental history vs Obese [DPH vs O]
Genes involved in Inositol phosphate metabolism, oxidative phosphorylation, amino acid metabolism pathways, ubiquinone biosynthesis, signal transduction pathways, signaling molecules and interaction pathways, nervous system pathways were upregulated in DPH vs O.

6. Diabetes with parental history vs diabetes without parental history (DPH vs DNPH1)
Genes involved in signal transduction, regulation of actin cytoskeleton, antigen processing and presentation, complement and coagulation cascades, axon guidance, Neurodegenerative disorders pathways were upregulated in DPH vs DNPH1.
Genes involved in carbohydrate pathways were downregulated in DPH vs DNPH1.

7. Diabetes with parental history vs Diabetes with no parental history2 (DPH vs DNPH2)
Genes involved in oxidative phosphorylation, metabolism of cofactors and vitamins pathways, immune system pathways, nervous system pathways, metabolic disorders pathways were upregulated in DPH vs DNPH2. Genes involved in lipid metabolism pathways, amino acid metabolism pathways, glycan biosynthesis and metabolism pathways, ubiquitin mediated proteolysis, signal transduction pathways, signaling molecules and interaction pathways, insulin signaling pathway, PPAR signaling pathway were downregulated in DPH vs DNPH2.

Changes in the expression of genes involved in inflammatory response
Plasma levels of CRP, TNF-α, and IL-6, which are markers of inflammation, are elevated in obesity, insulin resistance, essential hypertension, type 2 diabetes, and CHD both before and after the onset of these diseases [3-9]. In view of this, we specifically looked at the genes that are involved in inflammatory response in the present study. The data given in Table 2 depicts the inflammatory genes that were differentially expressed in obesity and type 2 diabetes mellitus.

Discussion
The incidence of obesity and type 2 diabetes mellitus and with it the consequent metabolic syndrome X is increasing throughout the world. It is estimated that by the year 2010, in the United States alone there may be about 50 to 75 million or more people with metabolic syndrome X. One important feature of metabolic syndrome X is the presence of insulin resistance. Subjects with abdominal obesity, hypertension, type 2 diabetes, hyperlipidemias, CHD, and stroke show insulin resistance and impaired glucose tolerance (IGT). Plasma levels of inflammatory markers such as CRP, TNF-α, and IL-6 are elevated in obesity, insulin resistance, essential hypertension, type 2 diabetes, CHD, and metabolic syndrome X [3-9], suggesting that all these disorders are associated with low-grade systemic inflammation. This is supported by the results of the present study wherein it was noted that genes involved in inflammatory response are differentially expressed in subjects with obesity and type 2 diabetes mellitus (see Table 2).

Early stages of obesity, type 2 diabetes mellitus, hypertension, and metabolic syndrome X are characterized by insulin resistance restricted to muscle tissue [16]. This may be the reason why exercise is beneficial in the prevention and treatment of insulin resistance since, it decreases insulin resistance and enhances glucose utilization in the muscles. Furthermore, exercise is anti-inflammatory in nature [17,18]. Exercise not only decreases the levels of inflammatory markers such as CRP, IL-6, and TNF-α but...
also simultaneously enhances the concentrations of anti-inflammatory cytokines IL-4, IL-10 and TGF-β compared to controls. IL-4, IL-10 and TGF-β are not only anti-inflammatory in nature but also suppress the production of pro-inflammatory cytokines IL-1, IL-2, and TNF-α [4].

Thus, under normal conditions there is a balance maintained between pro- and anti-inflammatory cytokines. In addition, in experimental animals exercise significantly reduced the magnitude of myocardial infarction and this cardioprotective action paralleled the increase in manganese superoxide dismutase (Mn-SOD) activity [19]. On the other hand, administration of antisense oligo-deoxyribonucleotide to Mn-SOD abolishes this cardioprotective action implying that enhancement of the activity of Mn-SOD is crucial to exercise-induced cardioprotective action. This increase in Mn-SOD activity is in response to exercise-induced free radical generation suggesting that under certain circumstances free radicals have highly beneficial actions, especially when they are produced in response to exercise. Pro-inflammatory cytokines enhance free radical generation. It was noted that administration of antibodies to TNF-α and IL-1 abolished the cardioprotective action of exercise and activation of Mn-SOD, indicating that exercise-induced increase in the production of pro-inflammatory cytokines augment generation of free radicals that, in turn, enhance Mn-SOD activity that is ultimately responsible for the cardioprotective action of exercise. This is supported by the observation that circulating levels of extracellular SOD are lower in subjects with CHD [20].

These results are supported by the present observation that in patients with type 2 diabetes mellitus genes concerned with reactive oxygen species and pro-inflammatory cytokines such as BCL2L1, MAPK1, IL8RA, and IL-6 were upregulated whereas SOD2 was downregulated (see Table 3). In addition, it was also noted that TGFBR1 (transforming growth factor-β receptor 1), which is an anti-inflammatory cytokine that inhibits the production of pro-inflammatory cytokines such as IL-6 and TNF-α was found to be up regulated in type 2 diabetes, most probably as a compensatory mechanism. These results suggest that low-grade systemic inflammation plays a significant role in the pathobiology of obesity, type 2 diabetes mellitus, and metabolic syndrome X [1-9]. This is supported by the observation that weight loss achieved by type 2 diabetes subjects was associated not only with a decrease in glycosylated hemoglobin (HbA1c), LDL cholesterol, insulin resistance, plasminogen activator inhibitor-1, CRP, IL-6, and TNF-α but also with significant improvements in arterial stiffness [21] suggesting that endothelial nitric oxide (eNO) production is increased whereas oxidative stress is decreased. Thus, the results of the present study and other investigations indicate the genes concerned with inflammation and immune response are differentially regulated in subjects with obesity and type 2 diabetes mellitus.

In this context, it is important to note that acetylcholine (ACh), the principal vagus neurotransmitter and an

Table 2: Genes involved in inflammatory response that were differentially expressed in subjects with obesity and type 2 diabetes mellitus.

| Condition | Genes that have been up regulated in obese (O) vs healthy (H) | Genes that have been down regulated in type 2 diabetes mellitus are: |
|-----------|-------------------------------------------------------------|------------------------------------------------------------------|
| DPH vs H  | ALK, GCH1, IFIH1, IFIT1, IL11RA, ITGB2, MAP3K4, MPP19, MPP3, RPS27A, SLK, TGFBR1, LITAF, IL-6, VEGFA | MBL2, AKTI, ATP1A1, SOD2 |
| DNPH1 vs H| CCL3, CDKN1A, CXCL12, HLA-A, IL11RA, KR78, LTB, MAP3K4, MPP10, MPP19, MPP20, MPP3, RPS27A, TNFSF10, UBC | ANXAI1, NFKB2, GLUD1, BCL2L1, MAPKI, SOCS3, IRS2 |
| DNPH2 vs H| CCL16, CR8, CXCL11, CXCL12, FN1, GCH1, HLA-A, IL11RA, LT, MPP19, MPP3, RH0A, S100A12, SLK, SYK, UBC | IL8RA, TGFBR1, LITAF, IL-6, VEGFA |

Table 3: Pattern of gene expression observed in patients with type 2 diabetes mellitus with parental history (DPH) of diabetes vs healthy normal (H), and obese vs healthy.
important neurotransmitter in the brain, is mostly concentrated in the brain, the spinal cord, and the rest of the nerve cells in the body and on the muscles of the body. The acetylcholine receptor modulates interactions between the nervous system and the immune system. Furthermore, the nervous system communicates with the immune system in a bi-directional pathway. Nervous tissues synthesize neuropeptides and cytokines and immune cells serve as the molecular basis of neural-immune interactions. Neural modulation can have both pro- and anti-inflammatory effects. ACh is known to have anti-inflammatory actions and suppress the production of pro-inflammatory cytokines [22]. The cholinergic anti-inflammatory pathway signals through the efferent vagus nerve and mediates its actions primarily by nicotinic acetylcholine receptors on tissue macrophages leading to decreased NF-κB activation, preservation of high mobility group box 1 (HMGB1) nuclear localization and decreased production of proinflammatory cytokines. In addition, ACh has a regulatory role on serotonin, dopamine and other neuropeptides [23,24], suggesting that a complex network of interaction exists between these molecules in the regulation of immune response and neurotransmission.

Since under normal physiological conditions sympathetic and parasympathetic pathways demonstrate counter talk, it is pertinent to note that phagocytes are capable of de novo synthesis of catecholamines and blockade of α2-adrenoceptors or catecholamine-generating enzymes suppressed inflammation [25]. Thus, parasympathetic nervous system suppresses inflammation by generating the anti-inflammatory molecule ACh, whereas sympathetic nervous system enhances the inflammatory response by secreting catecholamines. These results coupled with the observation that serotonin, another neurotransmitter, that has effects on behavior, mood, sleep, and appetite, has a direct role in the development and treatment of type 2 diabetes is interesting [26,27]. For instance, mice lacking the 5-HT2C receptor develop insulin resistance and type 2 diabetes and later overeat and become obese, whereas a drug that acts on 5-HT2C receptors improved glucose tolerance without leading to reductions in food intake or body weight by stimulating melanocyte-stimulating hormone (α-MSH) in the brain's arcuate nucleus, a portion of the hypothalamus that has a role in appetite control. These evidences are supported by the results of the present study wherein it was noted that genes involved in neuroactive ligand-receptor interaction, nervous system and neurodegenerative disorders pathways, axon guidance and immune and inflammatory pathways are altered.

In recent times since diet control, exercise, and drugs to reduce obesity are largely unsuccessful, the Roux-en-gastric bypass (RYGB) and other bariatric operations are becoming one of the most common abdominal surgical procedures in the USA [28]. RYGB produces on an average 49% to 65% weight loss within 2 to 5 years [29]. Besides weight loss, RYGB ameliorates diabetes, hyperlipidemia, and other obesity-related metabolic abnormalities [30,31]. While working with a rat model of RYGB in diet-induced obese rats, we observed that gastric bypass surgery produces significant weight loss due to reduced caloric intake with a reduction in meal size and meal number, accompanied by a decrease in serum glucose, insulin, leptin, triglyceride concentrations, and subcutaneous abdominal fat compared to the obese [32].

Further studies revealed that weight loss achieved by RYGB is in part due to a decrease in NPY (neuropeptide Y) in ARC (arcuate nucleus of hypothalamus), pPVN (parvo-cellular part of paraventricular nucleus of hypothalamus), and mPVN (magnocellular part of PVN) and an increase in α-MSH in ARC, pPVN, and mPVN compared with obese controls. 5HT1B-receptor in pPVN and mPVN increased in RYGB and PF (pair fed) compared to obese control [33]. These results emphasize the fact that weight loss seen after RYGB and diet control is due to specific changes in hypothalamic peptides. Serotonin innervation is widely distributed in the hypothalamus and it innervates NPY neurons both in the ARC and PVN. Serotonin has a suppressive effect on food intake. Thus, weight loss seen in RYGB and diet control groups could be attributed to alterations in the concentrations of specific hypothalamic signaling peptides that regulate appetite, food intake and satiety. Even in tumor bearing anorectic rats, which showed significant weight loss due to tumor burden, similar results were seen: an increase of serotonin in PVN and VMN (ventromedial nucleus of hypothalamus) and a concomitant decrease of dopamine in PVN, VMN and LHA (lateral hypothalamus), and of NPY in LHA, VMN and PVN; a decrease in NPY in ARC and of POMC (proopiomelanocortin) in ARC and PVN [33,34] and these abnormalities reverted to normal after tumor resection. In this context, it is noteworthy that even the concentrations of IL-6 and TNF-α were found to be elevated in ARC in tumor-bearing rats. These results emphasize the close interaction(s) between neurotransmitters, inflammatory molecules, and obesity and type 2 diabetes mellitus [35].

Obviously the present results need to be verified using a larger sample size, by estimating the concentrations of the specific proteins of the genes expressed, and studying more closely the interaction(s) between the nervous system, hypothalamic peptides and neurotransmitters, pro- and anti-inflammatory cytokines, and their relationship to appetite, satiety, development of obesity and type 2 diabetes mellitus. It is also likely that there could be individual variations in the expression of various genes.
concerned with appetite, satiety, and inflammation and this need to be taken into consideration while assigning importance to the degree of expression of some of these genes. Such variations in the expression of genes could be detected only by performing studies in a larger sample size. Nevertheless, the results of the present study suggest that there are significant differences in the expression of various genes concerned with carbohydrate, lipid, and protein metabolism, ubiquitin mediated proteolysis, signal transduction pathways, neuroactive ligand-receptor interaction, nervous system pathways, cell adhesion molecules, cytokine-cytokine receptor interaction, insulin signaling and immune system pathways, oxidative phosphorylation, and PPAR signaling pathways in subjects with obesity and type 2 diabetes compared to normal.

Authors’ contributions
UND designed the study, analyzed the data, and drafted the manuscript. AAR performed the study, and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We wish to express our gratitude to the technical staff of Ocimum Biosolutions of Hyderabad, India for their excellent technical and scientific support for this study.

References
1. Das UN: Is obesity an inflammatory condition? Nutrition 2001, 17:953-966.
2. Das UN: Obesity, metabolic syndrome X, and inflammation. Nutrition 2002, 18:430-432.
3. Das UN: A perinatal strategy to prevent coronary heart disease. Nutrition 2002, 19:1022-1027.
4. Albert MA, Glynn RJ, Ridker PM: Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score. Circulation 2003, 108:161-165.
5. Enngstrom G, Hedblad B, Stavlenow L, Lind P, Janzon L, Lindgarde F: Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003, 52:2097-2101.
6. Mosca L: C-reactive protein-to-scr or to normal? N Engl J Med 2002, 347:1615-1617.
7. Barzilai N, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly. Diabetes 2001, 50:2384-2389.
8. Das UN: Obesity and its relationship to coronary heart disease. Eur Heart J 2002, 23:2953-2954.
9. Das UN: Metabolic syndrome X is a low-grade systemic inflammatory condition with its origins in the perinatal period. Current Nutrition and Food Science 2003, 3:277-295.
10. Loguinov AV, Saira Mian I, Vulpe CD: Exploratory differential gene expression analysis in microarray experiments with no or limited replication. Genome Biol 2004, 5:R18.
11. Zhao HY, Yue PY, Fang KT: Identification of differentially expressed genes with multivariate outlier analysis. J Biopharm Stat 2004, 14(3):629-646.
12. Garrett RG: The chi-square plot: A tool for multivariate outlier recognition. Journal of Geochem Exploration 1989, 32:319-341.
13. Gervini D: A robust and efficient adaptive reweighted estimator of multivariate location and scatter. J Multivariate Analysis 2003, 84:116-144.
14. Filmoser P, Garrett RG, Reimann C: Multivariate outlier detection in exploration geochemistry. Computers and Geosciences 2005, 31:579-587.
15. Rousseseu P, Van Zomeran BC: Unmasking multivariate outliers and leverage points. J Am Statist Assoc 1990, 85:633-651.
16. Grundy SM, Brewer B Jr, Cleeman JI, Smith SC, Lenfant C, for the conference participants: Definition of metabolic syndrome. NHLBI/AHA conference proceedings. Circulation 2004, 109:433-438.
17. Das UN: Exercise and inflammation. Eur Heart J 2006, 27:1385-1386.
18. Das UN: Anti-inflammatory nature of exercise. Nutrition 2004, 20:323-336.
19. Yamashita N, Hoshiho S, Otsu K, et al.: Exercise provides direct biphasic Cardioprotection via manganese superoxide dismutase activation. J Exp Med 1999, 189:1699-1706.
20. Wang XL, Adachi T, Shim MA, Wilcken DE: Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. Arterioscler Thromb Vasc Biol 1998, 18:1915-1921.
21. Barinas-Mitchell E, Harper P, Kuller LH, Mancino J, Sutton-Tyrrell K, Kelley DE, Hegazi R: Effect of weight loss and nutritional intervention on arterial stiffness in type 2 diabetes. Diabetes Care 2006, 29:2218-2222.
22. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Yang H, AbuNur Y, Trapani K: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
23. Ramirez MJ, Cenarruzabeitia E, Lasheras B, Del Rio J: 5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices. Brain Res 1997, 757:17-23.
24. Das UN: Is type 2 diabetes mellitus a disorder of the brain? Nutrition 2002, 18:667-672.
25. Frierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma V, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, Gao H, Van Rooyen JN, Huber-Lang M, Neubig RR, Ward PA: Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007, 449:721-726.
26. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K: Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000, 43:373-376.
27. Nonogaki K, Strack AM, Dallman MF, Tecott LH: Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nature Med 1998, 4:1152-1156.
28. Schauer PR: Open and laparoscopic surgical modalities for the management of obesity. J Gastrointest Surg 2003, 7:468-475.
29. Fisher BL, Schauer P: Medical and surgical options in the treatment of severe obesity. Am J Surg 2002, 184:95-165.
30. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, de Ramon RA, Israel G, Dolezal JM: Who had thought it could! An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995, 222:339-350.
31. Meguid MM, Ramos EJB, Suzuki S, Xu Y, George ZM, Das UN, Hughes K, Quinn R, Chen C, Marx W, Cunningham PRG: A surgical model of human Roux-en-Y gastric bypass. J Gastrointest Surg 2004, 8:621-630.
32. Xu Y, Ramos EJB, Middleton F, Romanova I, Quinn R, Chen C, Das UN, Inui A, Meguid MM: Gene expression profiles post Roux-en-Y gastric bypass. Surgery 2004, 136:246-252.
33. Romanova I, Ramos EJB, Xu Y, Quinn R, Chan C, George ZM, Inui A, Das UN, Meguid MM: Neurobiologic changes in the hypothalamus associated with weight loss after gastric bypass. J Am Coll Surg 2004, 199:887-895.
34. Ramos EJB, Suzuki S, Meguid MM, Laviano A, Sato T, Chen C, Das UN: Changes in hypothalamic neuropeptide Y and monoaminergic system in tumor-bearing rats: pre- and post-tumor resection and at death. Surgery 2004, 136:270-276.
35. Das UN: Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? J Nutr Biochem 2007, 18:701-713.